Gordana V Krljanac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4717372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The impact of the complete atrioventricular block on in-hospital and long-term mortality in patients treated with primary percutaneous coronary intervention. Vojnosanitetski Pregled, 2023, 80, 16-22.	0.1	Ο
2	Concerns about the use of digoxin in acute coronary syndromes. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 474-482.	1.4	4
3	The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy. Vojnosanitetski Pregled, 2022, 79, 221-229.	0.1	1
4	Cardiomyopathies: Classification, diagnosis and treatment modalities. , 2022, 1, 38-48.		0
5	Acute Coronary Syndrome in the COVID-19 Era—Differences and Dilemmas Compared to the Pre-COVID-19 Era. Journal of Clinical Medicine, 2022, 11, 3024.	1.0	11
6	Metabolic Syndrome and Myocardial Infarction in Women. Current Pharmaceutical Design, 2021, 27, 3786-3794.	0.9	4
7	Smoking and sex differences in first manifestation of cardiovascular disease. Atherosclerosis, 2021, 330, 43-51.	0.4	12
8	Impact of kidney function on the occurrence of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction. , 2021, 25, 638-645.		3
9	Gender Disparities on Access to Care and Coronary Disease Management. Current Pharmaceutical Design, 2021, 27, 3210-3220.	0.9	3
10	Type 2 diabetes increases the longâ€ŧerm risk of heart failure and mortality in patients with atrial fibrillation. European Journal of Heart Failure, 2020, 22, 113-125.	2.9	23
11	Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation. European Journal of Preventive Cardiology, 2020, 27, 1931-1933.	0.8	5
12	ECHOS survey on echocardiography in Serbia during the COVID-19 pandemic. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 590-593.	0.1	1
13	Current echocardiography practice in Serbia - a national survey by the Echocardiographic Society of Serbia. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 430-435.	0.1	0
14	Cutting the Gordian knot of left ventricular diastolic dysfunction: Role of opportunistic screening models. European Journal of Preventive Cardiology, 2019, 26, 1666-1669.	0.8	0
15	Impact of acute hyperglycemia on layer-specific left ventricular strain in asymptomatic diabetic patients: an analysis based on two-dimensional speckle tracking echocardiography. Cardiovascular Diabetology, 2019, 18, 68.	2.7	22
16	Impact on long-term mortality of access and non-access site bleeding after primary percutaneous coronary intervention. Heart, 2019, 105, 1568-1574.	1.2	4
17	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
18	Using the RISK-PCI Score in the Long-Term Prediction of Major Adverse Cardiovascular Events and Mortality after Primary Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2019, 2019, 1-9.	0.5	5

#	Article	IF	CITATIONS
19	Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. European Journal of Preventive Cardiology, 2019, 26, 72-82.	0.8	27
20	Impact of Multivessel Coronary Artery Disease on Long Term Prognosis in Patients with ST-segment Elevation Myocardial Infarction. Journal of Cardiovascular Emergencies, 2019, 5, 66-71.	0.1	3
21	Sex Differences in Outcomes After STEMI. JAMA Internal Medicine, 2018, 178, 632.	2.6	183
22	Heart failure with improved ejection fraction: Is a newcomer in the family important?. European Journal of Preventive Cardiology, 2018, 25, 362-365.	0.8	2
23	Coronary Microcirculation in Heart Failure with Preserved Systolic Function. Current Pharmaceutical Design, 2018, 24, 2960-2966.	0.9	8
24	Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. Endocrine, 2018, 62, 136-143.	1.1	49
25	Prognostic impact of renal dysfunction on long-term mortality in patients with preserved, moderately impaired and severely impaired left ventricular systolic function following myocardial infarction. Anatolian Journal of Cardiology, 2018, 20, 21-28.	0.5	3
26	Author`s Reply. Anatolian Journal of Cardiology, 2018, 20, 256.	0.5	0
27	Sex and age differences and outcomes in acute coronary syndromes. International Journal of Cardiology, 2016, 217, S27-S31.	0.8	18
28	Gender differences in the prognostic impact of chronic kidney disease in patients with left ventricular systolic dysfunction following ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Hellenic Journal of Cardiology, 2016, 57, 109-115.	0.4	9
29	Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2016, 30, 151-158.	1.3	4
30	B-type Natriuretic Peptide and RISK-PCI Score in the Risk Assessment in Patients with STEMI Treated by Primary Percutaneous Coronary Intervention. Clinical Laboratory, 2016, 62, 317-25.	0.2	2
31	Impact of the combined presence of left ventricular systolic and renal dysfunction on the 5-year outcome after ST-elevation myocardial infarction. Vojnosanitetski Pregled, 2015, 72, 702-709.	0.1	1
32	Glucose-insulin-potassium therapy in acute myocardial infarction: Ten years follow-up. Srce I Krvni Sudovi, 2015, 34, 163-173.	0.1	0
33	Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 56-66.	0.4	19
34	Rationale and Design of the Onâ€Treatment PLAtelet Reactivityâ€Guided Therapy Modification FOR ST‣egment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. Journal of Interventional Cardiology, 2013, 26, 221-227.	0.5	3
35	Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart and Vessels, 2013, 28, 424-433.	0.5	12
36	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. International Journal of Cardiology, 2013, 167, 1632-1637.	0.8	7

#	Article	IF	CITATIONS
37	Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. International Journal of Cardiology, 2013, 162, 220-227.	0.8	27
38	Simple Risk Algorithm to Predict Serious Bleeding in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation Journal, 2013, 77, 1719-1727.	0.7	22
39	Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention. Coronary Artery Disease, 2012, 23, 1-8.	0.3	35
40	Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008. Journal of Cardiovascular Medicine, 2011, 12, 300-302.	0.6	5
41	In-Hospital and Long-Term Prognosis after Myocardial Infarction in Patients with Prior Coronary Artery Bypass Surgery; 19-Year Experience. Scientific World Journal, The, 2009, 9, 1023-1030.	0.8	4
42	The Timing of Infarction Pain in Patients with Acute Myocardial Infarction after Previous Revascularization. Scientific World Journal, The, 2008, 8, 598-603.	0.8	3
43	Effects of Glucose-Insulin-Potassium Infusion on ST-Elevation Myocardial Infarction in Patients Treated With Thrombolytic Therapy. American Journal of Cardiology, 2005, 96, 1053-1058.	0.7	30